AbbVie Inc (ABBV)vsTeleflex Incorporated (TFX)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
TFX
Teleflex Incorporated
$129.84
-1.72%
HEALTHCARE · Cap: $5.78B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2854% more annual revenue ($62.82B vs $2.13B). ABBV leads profitability with a 5.8% profit margin vs -47.4%. TFX appears more attractively valued with a PEG of 0.16. TFX earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TFX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
-0.7%
Fair Value
$106.26
Current Price
$129.84
$23.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Growing faster than its price suggests
Revenue surging 32.3% year-over-year
Earnings expanding 64.1% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Distress zone — elevated risk
Premium valuation, high expectations priced in
ROE of -32.7% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : TFX
The strongest argument for TFX centers on PEG Ratio, Revenue Growth, EPS Growth. Revenue growth of 32.3% demonstrates continued momentum. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : TFX
The primary concerns for TFX are Altman Z-Score, P/E Ratio, Return on Equity. A P/E of 1864.0x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while TFX is a hypergrowth play — different risk/reward profiles.
TFX carries more volatility with a beta of 0.82 — expect wider price swings.
TFX is growing revenue faster at 32.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 63/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Teleflex Incorporated
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?